GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Net-Net Working Capital

PEPT (Regenerex Pharma) Net-Net Working Capital : $-0.02 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Regenerex Pharma's Net-Net Working Capital for the quarter that ended in Jun. 2024 was $-0.02.

The industry rank for Regenerex Pharma's Net-Net Working Capital or its related term are showing as below:

PEPT's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.09
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Regenerex Pharma Net-Net Working Capital Historical Data

The historical data trend for Regenerex Pharma's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Net-Net Working Capital Chart

Regenerex Pharma Annual Data
Trend Nov10 Nov11 Nov12 Nov13 Nov14 Mar17 Mar18 Mar22 Mar23 Mar24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.01 - -0.02

Regenerex Pharma Quarterly Data
Nov14 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.02 -0.02 -0.02

Competitive Comparison of Regenerex Pharma's Net-Net Working Capital

For the Medical Instruments & Supplies subindustry, Regenerex Pharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerex Pharma's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regenerex Pharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Regenerex Pharma's Price-to-Net-Net-Working-Capital falls into.



Regenerex Pharma Net-Net Working Capital Calculation

Regenerex Pharma's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Mar. 2024 is calculated as

Net-Net Working Capital(A: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0+0.75 * 0+0.5 * 0-4.829
-0-0)/277.653
=-0.02

Regenerex Pharma's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2024 is calculated as

Net-Net Working Capital(Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0+0.75 * 0+0.5 * 0-5.042
-0-0)/278.226
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Regenerex Pharma  (OTCPK:PEPT) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Regenerex Pharma Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerex Pharma Business Description

Traded in Other Exchanges
N/A
Address
5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma Headlines

No Headlines